Starlix120 mg

Starlix is indicated as an adjunct to diet and exercise to improve glycemic control, particularly after-meal (postprandial) blood glucose levels, in adults with type 2 diabetes mellitus.

• Established/approved use: Monotherapy in patients whose hyperglycemia cannot be controlled by diet and exercise alone.
• Guideline-supported combination use: In combination with metformin in patients who do not achieve adequate control with either drug alone, when metformin's action on fasting glucose is combined with the postprandial effect of Starlix.
• Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis.

Starlix is typically used in patients whose predominant problem is elevated blood sugar after meals rather than fasting hyperglycemia.

Each tablet contains Nateglinide INN as the active pharmaceutical ingredient, commonly available in strengths of 60 mg and 120 mg for oral use, along with standard pharmaceutically approved excipients.

Starlix is an oral antidiabetic agent belonging to the meglitinide class of insulin secretagogues. Chemically it is a derivative of D-phenylalanine, structurally distinct from the sulfonylureas, though it acts on a related target on the pancreatic beta cell.

Starlix has a rapid onset and short duration of action, making it particularly suited to controlling the rise in blood glucose that follows meals when taken shortly before eating.

Antidiabetic agent - Meglitinide class (non-sulfonylurea insulin secretagogue)

Mechanism

Nateglinide lowers blood glucose by stimulating rapid, transient release of insulin from pancreatic beta cells. It binds to a sulfonylurea-receptor-associated site on the beta cell that is distinct from, but overlapping with, the sulfonylurea binding site, closing ATP-sensitive potassium channels. This causes cell membrane depolarization, opening of voltage-gated calcium channels, calcium influx, and exocytosis of insulin.

Pharmacokinetics

• Onset: Rapid, within about 20 minutes of dosing.
• Duration: Short-acting; insulinotropic effect largely resolves within 4 hours, restoring a more physiologic, meal-timed insulin response.
• Absorption: Rapidly and almost completely absorbed after oral dosing; taking it with food slightly delays absorption.
• Metabolism: Extensively metabolized in the liver, mainly via CYP2C9 and, to a lesser extent, CYP3A4.
• Excretion: Primarily renal, mostly as metabolites.

This pharmacologic profile is why Nateglinide is dosed before each main meal rather than once or twice daily.

Starlix tablets should be swallowed whole with water, ideally 1 to 30 minutes before starting a meal. It should be taken with a meal each time it is dosed; if a meal is skipped, that dose should be skipped as well.

Starlix is metabolized mainly by CYP2C9 and partly by CYP3A4, so interactions with drugs affecting these enzymes are clinically important.

• Gemfibrozil: Significantly increases Starlix blood levels and hypoglycemia risk via CYP2C9 inhibition; concurrent use requires caution and closer glucose monitoring.
• Other CYP2C9/CYP3A4 inhibitors (e.g., fluconazole): May increase Starlix exposure and hypoglycemia risk.
• Other antidiabetic agents (insulin, sulfonylureas, metformin): Additive blood-glucose-lowering effect increases the risk of hypoglycemia when combined with Starlix.
• Beta-blockers, clonidine: May mask the warning signs and symptoms of hypoglycemia.
• Drugs that can worsen glycemic control (e.g., corticosteroids, thiazide diuretics, thyroid hormones, sympathomimetics, oral contraceptives, phenothiazines): May reduce the glucose-lowering effect of Starlix, requiring dose reassessment.
• NSAIDs, salicylates, MAO inhibitors, ACE inhibitors, octreotide: May potentiate the hypoglycemic effect of Starlix.

Always inform the physician of all medicines being taken before starting Starlix.

The most common adverse effect of Starlix is hypoglycemia (see Precautions and Warnings for detail). Other reported side effects include:

• Upper respiratory tract infection, flu-like symptoms
• Dizziness
• Back pain
• Arthropathy/joint pain
• Diarrhea, other mild gastrointestinal upset
• Elevated uric acid (usually asymptomatic)

Most side effects are mild to moderate. Patients should seek prompt medical advice for symptoms of severe or persistent hypoglycemia or any signs of an allergic reaction.

Pregnancy: Data on Starlix use in human pregnancy are limited. Starlix should be used in pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Because good glycemic control is important throughout pregnancy, and because insulin is generally preferred for pharmacologic glycemic management in pregnancy, physicians usually transition patients from oral antidiabetic agents such as Starlix to insulin when pharmacologic therapy is required. Always consult a physician before use in pregnancy.

Lactation: It is not known whether Starlix passes into human breast milk. Because of the potential for hypoglycemia in a nursing infant, a decision should be made to discontinue nursing or discontinue Starlix, taking into account the importance of the drug to the mother, and only under medical supervision.

Hypoglycemia

All insulin secretagogues, including Starlix, can cause hypoglycemia. The risk increases if a meal is delayed or skipped after a dose, with strenuous exercise, alcohol intake, or when combined with other glucose-lowering drugs. Patients should be counseled to take Starlix only with a meal and to recognize and manage hypoglycemia symptoms (sweating, tremor, confusion, palpitations).

Hepatic Impairment

Use with caution in patients with hepatic impairment; Starlix has not been adequately studied in severe hepatic disease and increased hypoglycemia risk is possible.

Renal Impairment

Use with caution in significant renal impairment, including patients on dialysis, with appropriate glucose monitoring.

Combination Therapy

When Starlix is combined with other antidiabetic agents (particularly insulin or sulfonylureas), the risk of hypoglycemia is additive; dose adjustment and closer monitoring may be needed.

Loss of Glycemic Control

Fever, trauma, infection, or surgery may transiently reduce glycemic control; temporary insulin therapy may be required, and physicians should be consulted.

General

Starlix is not effective and should not be used for type 1 diabetes or diabetic ketoacidosis (see Contraindications). Regular monitoring of blood glucose and periodic HbA1c is recommended during treatment.

Overdose of Starlix can cause profound, prolonged hypoglycemia, with symptoms such as sweating, tremor, confusion, palpitations, seizures, or loss of consciousness.

If overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Mild, early hypoglycemia with the patient conscious may be managed by giving oral glucose or a sugary drink/food while arranging medical review; more severe hypoglycemia requires urgent medical treatment (e.g., intravenous glucose) under professional supervision. Do not attempt to manage a severe overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

Starlix can be used in elderly patients; because older adults may be more sensitive to hypoglycemia, initiate and titrate cautiously with close monitoring.

Renal Impairment

Use with caution in significant renal impairment (see Precautions and Warnings); no dedicated dose adjustment is established for mild-moderate disease.

Hepatic Impairment

Use with caution; not recommended in severe hepatic impairment (see Precautions and Warnings).

Pregnancy and Lactation

See Pregnancy and Lactation section for detailed guidance; use only under medical supervision.

Pediatric Patients

Safety and efficacy of Starlix have not been established in children (see Pediatric Uses).

Starlix is generally used long-term as part of ongoing management of type 2 diabetes mellitus, alongside diet and exercise. The physician periodically reassesses the need for continued therapy and dose based on blood glucose control (including HbA1c) and tolerability; it should be taken with each qualifying meal for as long as prescribed.

Meglitinides (non-sulfonylurea insulin secretagogues); oral antidiabetic agents

Nateglinide acts on pancreatic beta cells by binding to a site associated with the ATP-sensitive potassium (K-ATP) channel that is distinct from, though near, the sulfonylurea binding site. This binding closes the K-ATP channel, depolarizing the beta-cell membrane and opening voltage-dependent calcium channels. The resulting influx of calcium triggers exocytosis of stored insulin.

Because Nateglinide binds and dissociates from this site quickly, its insulin-releasing effect is rapid in onset and short in duration compared with sulfonylureas, which mimics the body's normal early-phase insulin response to a meal and specifically targets the after-meal glucose rise, with a lower risk of prolonged hypoglycemia between meals.

C

The safety and efficacy of Starlix have not been established in pediatric patients. Starlix is therefore not recommended for use in children and adolescents; management of type 2 diabetes in this age group should follow pediatric-specific guidance from a physician.